First, although a study reported that the selective first-in-class catalytic inhibitor of METTL3 (i.e., STM2457) can be used in treatment strategies for acute myeloid leukemia [48], the inhibitor of METTL3 has not yet been identified for the treatment of CRC. The gene discussed is METTL3; the disease is acute myeloid leukemia.